Clinical Trial Detail

NCT ID NCT02978716
Title Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors G1 Therapeutics, Inc.
Indications

triple-receptor negative breast cancer

Therapies

Carboplatin + Gemcitabine

Carboplatin + Gemcitabine + Trilaciclib

Age Groups: adult senior

No variant requirements are available.